THR-184
Also known as: BMP-7 peptide mimetic, THR-184, THR‑184, Thrasos-184, Thrombin‑derived peptide 1
Source THR-184 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Synthetic peptide derived from the C‑terminal region of thrombin (THR‑184) investigated for topical ocular and wound‑healing applications due to anti‑inflammatory and antimicrobial properties.
Mechanism of Action
Modulates innate immune response by binding bacterial lipopolysaccharide and dampening pro‑inflammatory signaling; promotes epithelial wound healing
Routes of Administration
Goals & Uses
- Dry eye diseaseOphthalmologyModerate
- Corneal epithelial wound healingWound HealingModerate
- Reduction of renal tubular apoptosisCell SurvivalLow
- Prevention of acute kidney injuryRenoprotectionModerate
- Attenuation of ischemia-reperfusion injuryCytoprotectionModerate
- Reduction of renal fibrosisAntifibroticLow
Contraindications
- Hypersensitivity to THR-184 or excipientsAllergic/ImmunologicHigh
- Known hypersensitivity to peptide componentsAllergyHigh
- Active malignancy with BMP pathway involvementOncologyModerate
Adverse Effects
- HeadacheNeurologicUncommonPain in the head or upper neck
- Electrolyte disturbancesMetabolicUnknown
- HypotensionCardiovascularUnknownLow blood pressure
- NauseaGastrointestinalUnknownFeeling of sickness or urge to vomit
- Injection site / infusion reactionsLocal/SystemicUnknown
- Transient ocular irritationLocalCommon
Drug Interactions
- Topical corticosteroidsLow
- TGF-β inhibitorsLow
- DiureticsLowMay worsen dehydration or electrolyte imbalance
Population Constraints
- Patients with end-stage renal diseaseRenal ImpairmentRelative
- Pediatric patientsAgeRelative
- Pediatric patients (<12 y)AgeRelative
- Pregnant or lactating womenReproductiveRelative
- Pregnant womenReproductiveRelative
- Patients with known BMP pathway malignanciesOncologyRelative
Regulatory Status
- European UnionInvestigationalUnder evaluation; no marketing authorization.
- United StatesInvestigationalPhase II clinical trials for dry eye; not FDA‑approved.
- United KingdomInvestigationalNo MHRA approval; participated in multi-center trials
Not approved by FDA, EMA, or other regulatory agencies. Investigated under IND/clinical trial frameworks. Development was primarily led by Thrasos Therapeutics (Canada). Phase 2 trials were conducted; no Phase 3 program has been publicly announced.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is THR-184?
Synthetic peptide derived from the C‑terminal region of thrombin (THR‑184) investigated for topical ocular and wound‑healing applications due to anti‑inflammatory and antimicrobial properties.
What is THR-184 used for?
THR-184 is educationally associated with: Dry eye disease, Corneal epithelial wound healing, Reduction of renal tubular apoptosis, Prevention of acute kidney injury, Attenuation of ischemia-reperfusion injury, Reduction of renal fibrosis. Educational only — not medical advice.
How is THR-184 administered?
Recorded routes of administration: Intravenous, Subcutaneous, Topical (ocular).
What are the potential side effects of THR-184?
Reported adverse effects include: Headache, Electrolyte disturbances, Hypotension, Nausea, Injection site / infusion reactions, Transient ocular irritation. This list is not exhaustive — consult a qualified clinician.
Who should avoid THR-184?
Recorded contraindications: Hypersensitivity to THR-184 or excipients, Known hypersensitivity to peptide components, Active malignancy with BMP pathway involvement. Consult a qualified clinician before use.